Extended Data Fig. 3: Treatment-emergent CRS by dose and severity grade with the 0.7/4/20 mg regimen. | Nature Cancer

Extended Data Fig. 3: Treatment-emergent CRS by dose and severity grade with the 0.7/4/20 mg regimen.

From: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Extended Data Fig. 3

The percentage of patients in the 0.7/4/20 mg regimen cohort who experienced at least one CRS event are shown according to CRS grade (1, 2, or 3). n numbers represent the number of patients treated at each of the dose points shown. CRS, cytokine release syndrome.

Source data

Back to article page